Inhaled nitric oxide for the treatment of COVID-19: an open-label, parallel, randomised controlled trial.

The same analysis at 5 and 7 days also shows a higher proportion of patients without ventilatory support in the iNO group but did not reach statistical significance; p=0.051 for both ( table 4 and supplementary figure S3 ).

also in 111,027 other papers